Valneva Overview
- Founded
-
1999
- Status
-
Public
- Employees
-
628
- Stock Symbol
-
VLA
- Investments
-
4
- Share Price
-
$6.79
- (As of Wednesday Closing)
Valneva General Information
Description
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travellers; one for the prevention of Japanese encephalitis (IXIARO) and the second (DUKORAL) for the prevention of cholera and diarrhoea. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, and third-party products; Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; and Technologies and services which relates to services and inventions at a commercialization stage. The group is based in France and operates internationally.
Contact Information
Website
www.valneva.com
Formerly Known As
Vivalis
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
PAR
Primary Office
- 6, Rue Alain Bombard
- 44800 Saint-Herblain
- France
+33 02 00 00 00 00
Valneva Timeline
Valneva Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.79 | $6.78 | $4.81 - $20.61 | $940M | 138M | 358K | $0.91 |
Valneva Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 389,763 | 2,651,647 | 814,142 | 279,305 |
| Revenue | 571,418 | 411,540 | 125,756 | 141,269 |
| EBITDA | 103,378 | (46,068) | (51,163) | 11,302 |
| Net Income | 79,451 | (86,810) | (73,402) | (1,952) |
| Total Assets | 686,137 | 925,423 | 552,457 | 296,535 |
| Total Debt | 158,853 | 129,815 | 129,701 | 95,457 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Valneva Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Valneva Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for trav
Biotechnology
Saint-Herblain, France
628
As of 2022
00000
00000000
00000
000000
g elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut en
0000 000000000
Tubingen, Germany
0000
As of 0000
00.000
00000000
00.000
000000
in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint o
0000000000000
Gaithersburg, MD
0000
As of 0000
00000
000000000
00000
Add Comparison
Valneva Competitors (80)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CureVac | Formerly VC-backed | Tubingen, Germany | 0000 | 00.000 | 00000000 | 00.000 |
| 0000000 | Corporation | Gaithersburg, MD | 0000 | 00000 | 000000000 | 00000 |
| 0000000 | Corporation | Beijing, China | 0000 | 00000 | 000000 - 000 | 00000 |
| 000000 00000000000 | Corporation | Plymouth Meeting, PA | 000 | 000.00 | 00000000 | 000.00 |
| 0000000 0000000000 | Corporation | Emeryville, CA | 000 | 00000 | 000000000 | 00000 |
Valneva Patents
Valneva Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3174666-A1 | Improved methods of producing a lipidated protein | Pending | 09-Apr-2020 | 000000000 | |
| CA-3174599-A1 | Improvements in vaccine formulations for medical use | Pending | 09-Apr-2020 | 000000000 | |
| AU-2021253605-A1 | Inactivated sars-cov-2 virus vaccine | Pending | 06-Apr-2020 | 000000000 | |
| CA-3168784-A1 | Inactivated sars-cov-2 virus vaccine | Pending | 06-Apr-2020 | 000000000 | |
| EP-3955959-A2 | Inactivated sars-cov-2 virus vaccine | Pending | 06-Apr-2020 | A61K39/12 |
Valneva Executive Team (15)
Valneva Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alain Munoz Ph.D | Self | Scientific Advisory Board Member | 000 0000 |
| Anne-Marie Graffin | Valneva | Supervisory Board Member | 000 0000 |
| Anne-Marie Graffin | Self | Board Member | 000 0000 |
| Frederic Grimaud | Valneva | Chairman & Board Member | 000 0000 |
| James Sulat | Self | Board Member & Vice Chairman | 000 0000 |
Valneva Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Valneva Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Valneva Investments & Acquisitions (4)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 00000 | 09-Feb-2015 | 0000000000 | 000.00 | Biotechnology | 000000 00 |
| 00000 0000000 | 11-Dec-2014 | 00000 0000 | 00.000 | Biotechnology | 000000 00 |
| 000000000 | 16-Dec-2012 | 000000 00 | Biotechnology | ||
| Humalys | 01-Jan-2010 | Merger/Acquisition | 000.00 | Biotechnology |
Valneva ESG
Risk Overview
Risk Rating
Updated January, 14, 2023
29.03 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 1,008
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 465
Rank
00.00
Percentile
